Pharmaceutical Royalty Tokenization: $20B Market

Global spending on medicines passed $1.6 trillion in 2024 and, on the IQVIA Institute's projections, will keep climbing through the rest of the decade. Sitting on top of that revenue is a quiet, multi-decade asset class: the contractual right to a percentage of a drug's net sales. Royalty Pharma, the largest dedicated buyer, has deployed more than $25 billion acquiring those streams since 1996, and the broader royalty-monetization market now clears in the low tens of billions a year. Pharmaceutical royalty tokenization is the mechanism that brings these cash flows onto regulated digital rails.

What a Pharmaceutical Royalty Actually Is

A pharmaceutical royalty is a contractual entitlement to a fixed percentage of the net sales of an approved, marketed drug. It is not equity in the company that sells the drug, and it is not a loan. The royalty holder has no operating role, no manufacturing exposure, and no claim on the seller's other assets — only a right to a slice of a specific product's revenue, paid quarterly, for as long as the underlying agreement runs.

Royalties originate in the way drugs are discovered and licensed. A university, research hospital, or biotech that invents a compound typically licenses it to a larger pharmaceutical company in exchange for milestone payments and an ongoing royalty on sales. Those royalty rights then trade in a secondary market: specialist funds buy them outright for an upfront sum, giving the original holder immediate cash in place of an uncertain future stream. The asset is well defined, the cash flows are documented in audited sales reports, and the payment mechanics are contractual rather than discretionary — which is exactly what makes it a candidate for tokenization.

Why Royalties Behave Differently From Equity and Credit

The reason institutional capital has built dedicated funds around drug royalties is that the return profile does not move with public markets. A royalty on an approved therapy pays out based on prescription volume, which tracks disease prevalence and clinical demand far more than it tracks interest rates or equity sentiment. Patients take medication through recessions. That low correlation is the core of the allocation case: royalties sit between fixed income and private equity, delivering contracted cash yield with limited sensitivity to the broader cycle.

The defining risk is specific rather than systemic. A royalty terminates or steps down at loss of exclusivity — the point at which patent protection expires and generic or biosimilar competition erodes branded sales. Underwriting a royalty is therefore an exercise in forecasting a single product's revenue curve to its patent cliff, and a single-drug royalty carries real concentration risk if the science or the market disappoints. Diversified portfolios of royalties spread that exposure across therapies, indications, and expiry dates, which is why scaled buyers assemble pools rather than holding one stream. The cash flow is durable; the discipline is in the diligence.

Who Sells Royalties and Why

The sell side of this market is broader than most investors assume. Academic institutions and research foundations are among the largest sources: in a landmark 2014 transaction, the Cystic Fibrosis Foundation sold its royalty interest in a portfolio of therapies for $3.3 billion, converting decades of patient-funded research into capital it could redeploy into new science. Universities monetize royalties to fund endowments and laboratories. Inventors and early shareholders sell to diversify out of a single concentrated position.

The most active sellers, though, are biotechnology companies themselves. A clinical-stage or newly commercial biotech needs capital, and its alternatives are dilutive equity raises at depressed valuations or debt it cannot service before revenue scales. Selling a royalty on a current or future product — sometimes a synthetic royalty created specifically for the financing — raises non-dilutive capital without surrendering ownership or control. That motive drives a steady, growing pipeline of transactions, and it is the same logic that brings asset owners to other contracted-cash-flow markets such as litigation finance tokenization. Pharmaceutical royalty tokenization extends that financing option to holders who today have no efficient path to a buyer.

What Tokenization Brings to Royalty Holders and Buyers

The traditional royalty market is bilateral, opaque, and built for very large transactions. A foundation or biotech selling a stream negotiates privately with a handful of specialist funds, the diligence runs for months, and minimum deal sizes effectively exclude smaller royalty positions and smaller buyers. Liquidity after the sale is near zero — a fund that buys a royalty generally holds it to expiry.

Tokenization restructures both sides of that market. A royalty interest is placed into a special-purpose entity, and fractional ownership of that entity is issued as a regulated security — under Reg D, Reg S, or Reg A+ — with each token representing a defined economic interest in the underlying payment stream. A holder can sell a portion of a royalty rather than the whole, and a qualified buyer can take a measured position sized to a portfolio rather than a single multi-hundred-million-dollar block. The quarterly royalty payment flows through to token holders on a transparent, auditable schedule. Commertize's issuance framework handles the securities wrapper, custody, and investor onboarding, and comparable income-stream structures are visible across the marketplace.

The Compliance Architecture That Makes It Institutional

Royalty cash flows are health-sector financial assets, and the compliance bar is correspondingly high. Institutional-grade pharmaceutical royalty tokenization requires regulated custody, a qualified transfer agent maintaining the cap table, and KYC, AML, and accreditation verification at issuance and on every secondary transfer. It requires fund-grade reporting — distribution schedules, audited financials, and tax outputs that a compliance officer or LP can use directly. Those rails are now production-grade across the tokenized real-world asset market, which crossed $26 billion in on-chain value in early 2026.

The asset-specific work is the underwriting and disclosure layer. Tokenized royalties need standardized data feeds drawn from the licensee's reported net sales, independent valuation refreshed at least quarterly against the product's revenue trajectory and patent timeline, and clear documentation of loss-of-exclusivity assumptions so buyers price the cliff correctly. They need legal templates that translate established royalty purchase agreements into a tokenized entity without weakening the holder's contractual standing. Get those pieces right inside a single compliance perimeter, and a market that has served a dozen specialist funds becomes accessible to the far larger universe of institutional allocators seeking durable, non-correlated yield.

Have an asset you're evaluating for tokenization? Send the offering memo to deals@commertize.com or start at commertize.com/tokenize, and we will return a written tokenizability and capital-structure memo within 48 hours — free, no obligation.

Confidential review. No cost, no commitment, no calls unless it is a fit.